KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Treasury Shares (2016 - 2025)

CRISPR Therapeutics AG's Treasury Shares history spans 8 years, with the latest figure at $60000.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 32.29% year-over-year to $115316.0; the TTM value through Dec 2025 reached $115316.0, down 32.29%, while the annual FY2025 figure was $115316.0, 32.29% down from the prior year.
  • Treasury Shares for Q4 2025 was $60000.0 at CRISPR Therapeutics AG, roughly flat from $60000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $195316.0 in Q1 2021 and bottomed at $115316.0 in Q4 2025.
  • The 5-year median for Treasury Shares is $180316.0 (2021), against an average of $172316.0.
  • The largest annual shift saw Treasury Shares changed 0.0% in 2021 before it tumbled 32.29% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $63000.0 in 2021, then changed by 0.0% to $63000.0 in 2022, then decreased by 1.59% to $62000.0 in 2023, then changed by 0.0% to $62000.0 in 2024, then fell by 3.23% to $60000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Treasury Shares are $60000.0 (Q4 2025), $60000.0 (Q3 2025), and $62000.0 (Q2 2025).